Company Filing History:
Years Active: 2020
Title: Kuan-Lang Lai: Innovator in Hepatocellular Carcinoma Treatment
Introduction
Kuan-Lang Lai is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical biotechnology, particularly in the treatment of hepatocellular carcinoma (HCC). His innovative work focuses on improving patient outcomes following surgical interventions.
Latest Patents
Kuan-Lang Lai holds a patent for "Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection." This patent details the use of Muparfostat in reducing intrahepatic tumor recurrence and increasing the disease-free survival period in HCC patients with microvascular invasion after curative liver resection. The identification of these patients is achieved by examining resected liver tumor samples for the presence of microvascular invasion.
Career Highlights
Kuan-Lang Lai is associated with Medigen Biotechnology Corporation, where he applies his expertise in biotechnology to develop innovative treatments. His work has the potential to significantly impact the lives of patients suffering from liver cancer.
Collaborations
Kuan-Lang Lai collaborates with various professionals in the field, including his coworker Stanley Chang, to advance research and development in cancer treatment.
Conclusion
Kuan-Lang Lai's contributions to the treatment of hepatocellular carcinoma exemplify the importance of innovation in medical biotechnology. His patent on Muparfostat represents a significant step forward in improving patient care and outcomes.